Latest Headlines

Latest Headlines

China's BeiGene completes $97M financing for targeted oncology candidates

China's BeiGene said it has completed financing of more than CNY450 million ($75 million) from initial angel and strategic investors as well as new investors Hillhouse Capital and CITIC PE, joined by an unnamed "blue chip U.S. public investment fund" specializing in life sciences.

Contrave trial tussle brews between Takeda, Orexigen with Cleveland Clinic on the scene

A tussle over the termination of a trial to assess the cardiovascular safety of obesity drug Contrave is in swing, with Orexigen Therapeutics and Takeda Pharmaceutical entering a dispute process, according to Reuters, with earlier data breaches the subject of a separate issue.

Dr. Reddy's says pick a partner to dance with Japan on pharma trade

Whatever the India government may be doing to foster pharma trade with Japan, Dr Reddy's Laboratories feels it has a better way: partner with Japan counterparts.

Celgene partners with Alliqua for a third cell-based, wound care product

Micro-cap Alliqua Biomedical has amended its exclusive licensing deal with Celgene Cellular Therapeutics, a subsidiary of Celgene, to add the right to develop and market the biopharma's connective tissue matrix product. This is the third tissue product that Alliqua has licensed from Celgene, also including the Biovance Human Amniotic Membrane Allograft and the Placental Extra Cellular Matrix.

Takeda, Orexigen end CV study for obesity drug Contrave

Takeda Development Center Americas, a unit of Japan's Takeda Pharmaceutical, and Orexigen Therapeutics have ended a cardiovascular outcomes trial that compared the obesity drug Contrave to a placebo in addition to diet and exercise counselling, in 8,909 overweight and obese patients with certain CV risk factors, the companies said.

Eli Lilly puts cancer immunotherapies in spotlight with $360M-plus BioNTech deal

Eli Lilly has turned to Germany's BioNTech to form its latest collaboration on the cancer immunotherapy front, handing over $60 million--$30 million as a signing bonus and $30 million for equity--and promising up to $300 million in milestones for each new program that can go the distance.

In a move toward an artificial pancreas, Debiotech gains option for Bayer's iSense CGM

Debiotech has gained an option with Oregon-based iSense CGM to acquire exclusive rights to use its continuous glucose monitoring technology with patch insulin pumps for diabetes treatment. The companies expect that the integration of Debiotech's Jewel Pump with the iSense continuous glucose monitor technology could lead to the creation of an accurate artificial pancreas--a device that continuously measures insulin levels and then automatically dispenses insulin accordingly in response.

Celgene's R&D speed dating is starting to pay off, CEO says

Commit up to $485 million to buy a cancer genomics company. Pay another $450 million for a share of an immuno-oncology candidate. Throw in a $30 million licensing deal and an $80 million bet on a longtime collaborator and you've got a month in the life of Celgene, biotech's most prolific dealmaker.

From the pharma C-suite: Notable, quotable remarks on Asia, emerging markets for Q1 (Part 6)

FiercePharmaAsia  combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.

Takeda joins with Japan's National Cancer Center on genomic screening

Takeda Pharmaceutical and Japan's National Cancer Center have entered into a plan to find and develop anticancer agents and a way to get them to Japanese patients quickly. The plan, in part, is to build on their collaboration on a genomic screening project led by the NCC.